 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...116117118119120121122123124125126...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients (clinicaltrials.gov) - Nov 23, 2016
P1, N=100, Recruiting, Sponsor: James Graham Brown Cancer Center
Trial primary completion date: Aug 2016 --> Aug 2018
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: NoTOPain: Novel Treatment Option for Neuropathic Pain (clinicaltrials.gov) - Nov 8, 2016
P2, N=15, Completed, Sponsor: Sorlandet Hospital HF
Trial primary completion date: Aug 2016 --> Aug 2018 Active, not recruiting --> Completed
- || monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Nov 4, 2016
P1, N=175, Recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed N=232 --> 175 | Trial primary completion date: Sep 2019 --> Jun 2019
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date, Monotherapy, Metastases: PIK-ORL: Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive (clinicaltrials.gov) - Nov 3, 2016
P2, N=70, Recruiting, Sponsor: Centre Leon Berard
N=232 --> 175 | Trial primary completion date: Sep 2019 --> Jun 2019 Trial primary completion date: Mar 2016 --> Mar 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Metastases: Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 3, 2016
P2, N=21, Terminated, Sponsor: University of Pittsburgh
Trial primary completion date: Mar 2016 --> Mar 2017 N=37 --> 21 | Recruiting --> Terminated; PI leaving the institution
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New trial, Tumor cell, Metastases: Evaluation of CTCs Combined With Tumor Marker Detection of Efficacy of Chemotherapy in mCRC (clinicaltrials.gov) - Oct 31, 2016
P=N/A, N=100, Not yet recruiting, Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- || telisotuzumab (h224G11) / AbbVie
Trial primary completion date, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Oct 27, 2016
P1, N=124, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=37 --> 21 | Recruiting --> Terminated; PI leaving the institution Trial primary completion date: Oct 2016 --> Apr 2017
- pegvorhyaluronidase alfa (PEGPH20) / Halozyme, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Trial primary completion date: Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection (clinicaltrials.gov) - Oct 26, 2016
P=N/A, N=2, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Oct 2016 --> Apr 2017 Recruiting --> Completed | N=10 --> 2 | Trial primary completion date: Sep 2017 --> Sep 2016
- || Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial suspension, Combination therapy, Metastases: KESTREL: Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Oct 25, 2016
P3, N=760, Suspended, Sponsor: AstraZeneca
Recruiting --> Completed | N=10 --> 2 | Trial primary completion date: Sep 2017 --> Sep 2016 Recruiting --> Suspended
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, New P2/3 trial, Monotherapy, Metastases: Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC (clinicaltrials.gov) - Oct 25, 2016
P2/3, N=200, Not yet recruiting, Sponsor: Ruijin Hospital
- Votrient (pazopanib) / Novartis, BeiGene, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Oct 21, 2016
P1, N=33, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Suspended Trial primary completion date: Jul 2015 --> Jun 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: NoTOPain: Novel Treatment Option for Neuropathic Pain (clinicaltrials.gov) - Oct 19, 2016
P2, N=14, Active, not recruiting, Sponsor: Sorlandet Hospital HF
Trial primary completion date: Jul 2015 --> Jun 2017 Recruiting --> Active, not recruiting
- Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial, Metastases: Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) (clinicaltrials.gov) - Oct 18, 2016
P1, N=10, Not yet recruiting, Sponsor: The Netherlands Cancer Institute
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Trial primary completion date, Metastases: A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU) (clinicaltrials.gov) - Oct 14, 2016
P2, N=17, Terminated, Sponsor: Royal Marsden NHS Foundation Trust
Recruiting --> Active, not recruiting N=90 --> 17 | Recruiting --> Terminated | Trial primary completion date: Sep 2010 --> Dec 2014; Data from other trials failed to demonstrate meaningful survival advantage
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Metastases: A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC (clinicaltrials.gov) - Oct 14, 2016
P1/2, N=20, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=90 --> 17 | Recruiting --> Terminated | Trial primary completion date: Sep 2010 --> Dec 2014; Data from other trials failed to demonstrate meaningful survival advantage N=98 --> 20 | Active, not recruiting --> Terminated; Low accrual
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed, Metastases: Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer (clinicaltrials.gov) - Oct 13, 2016
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=98 --> 20 | Active, not recruiting --> Terminated; Low accrual Recruiting --> Active, not recruiting
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Surgery: RTOG-0617: High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 12, 2016
P3, N=500, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Recruiting --> Active, not recruiting Trial primary completion date: May 2016 --> Jun 2013
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Surgery, Metastases: Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer (clinicaltrials.gov) - Oct 12, 2016
P3, N=720, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Trial primary completion date: May 2016 --> Jun 2013 Trial primary completion date: Jun 2016 --> Jan 2011
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response (clinicaltrials.gov) - Oct 11, 2016
P2, N=30, Recruiting, Sponsor: Poitiers University Hospital
Trial primary completion date: Jun 2016 --> Jan 2011 Trial primary completion date: Dec 2012 --> Dec 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas (clinicaltrials.gov) - Oct 11, 2016
P2, N=51, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2012 --> Dec 2016 Trial primary completion date: Nov 2016 --> Nov 2017
- ||| temuterkib (LY3214996) / Eli Lilly
Enrollment open, Combination therapy, Metastases: A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer (clinicaltrials.gov) - Oct 7, 2016
P1, N=136, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Nov 2016 --> Nov 2017 Not yet recruiting --> Recruiting
- Stivarga (regorafenib) / Bayer
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination (clinicaltrials.gov) - Oct 5, 2016
P1b, N=44, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Jan 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) (clinicaltrials.gov) - Oct 3, 2016
P2, N=23, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Jan 2017 Recruiting --> Active, not recruiting | N=50 --> 23 | Trial primary completion date: Dec 2016 --> Jun 2016
- || Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Trial primary completion date, Metastases: Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 3, 2016
P1/2, N=150, Active, not recruiting, Sponsor: Array BioPharma
Recruiting --> Active, not recruiting | N=50 --> 23 | Trial primary completion date: Dec 2016 --> Jun 2016 Trial primary completion date: Aug 2016 --> Mar 2017
- | monalizumab (IPH2201) / AstraZeneca, Innate
Phase classification, Metastases: IPH2201-203: Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Sep 30, 2016
P1b/2, N=70, Recruiting, Sponsor: Innate Pharma
Trial primary completion date: Aug 2016 --> Mar 2017 Phase classification: P1/2 --> P1b/2
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Trial primary completion date, Metastases: Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma (clinicaltrials.gov) - Sep 26, 2016
P2, N=6, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Phase classification: P1/2 --> P1b/2 Terminated --> Completed | N=40 --> 6 | Trial primary completion date: Feb 2010 --> Jul 2011
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Sep 26, 2016
P2, N=128, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Terminated --> Completed | N=40 --> 6 | Trial primary completion date: Feb 2010 --> Jul 2011 Trial primary completion date: Jul 2017 --> Jul 2018
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, HEOR: Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades (clinicaltrials.gov) - Sep 22, 2016
P=N/A, N=50, Recruiting, Sponsor: National Center for Tumor Diseases, Heidelberg
Trial primary completion date: Jul 2017 --> Jul 2018 Trial primary completion date: Jul 2016 --> Jul 2017
- | prexasertib (ACR-368) / Acrivon Therap
Phase classification, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Sep 22, 2016
P1b, N=185, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jul 2016 --> Jul 2017 Phase classification: P1 --> P1b
- |||||| Opdivo (nivolumab) / BMS
Enrollment open, Metastases: Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer (clinicaltrials.gov) - Sep 21, 2016
P3, N=120, Recruiting, Sponsor: RTOG Foundation, Inc.
Phase classification: P1 --> P1b Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: FOCULM: FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 20, 2016
P2, N=138, Recruiting, Sponsor: Sun Yat-sen University
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2016 --> Feb 2018
- | Tabrecta (capmatinib) / Incyte, Novartis
Enrollment closed, Enrollment change, Combination therapy: Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy (clinicaltrials.gov) - Sep 20, 2016
P1/2, N=13, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2016 --> Feb 2018 Recruiting --> Active, not recruiting | N=60 --> 13
- ||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Combination therapy, Metastases: KESTREL: Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Sep 19, 2016
P3, N=760, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | N=60 --> 13 N=628 --> 760
- || imgatuzumab (RO5083945) / Centessa
Trial primary completion date: A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Sep 15, 2016
P1, N=62, Completed, Sponsor: Hoffmann-La Roche
N=628 --> 760 Trial primary completion date: Dec 2012 --> Jun 2012
- || Ojemda (tovorafenib) / Day One Biopharma, alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy, Metastases: A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies (clinicaltrials.gov) - Sep 15, 2016
P1b, N=125, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Trial primary completion date: Dec 2012 --> Jun 2012 Trial primary completion date: Jun 2016 --> Mar 2018
- ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment closed, Enrollment change, Metastases: Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Sep 9, 2016
P1b, N=14, Active, not recruiting, Sponsor: James J Lee
Trial primary completion date: Jun 2016 --> Mar 2018 Recruiting --> Active, not recruiting | N=22 --> 14
- || simlukafusp alfa (RG7461) / Roche, Herceptin (trastuzumab) / Roche
Trial primary completion date, Combination therapy: A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) (clinicaltrials.gov) - Sep 2, 2016
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=22 --> 14 Trial primary completion date: May 2017 --> Mar 2019
- Avastin (bevacizumab) / Roche
Enrollment change, Trial withdrawal, Combination therapy, Metastases: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer. (clinicaltrials.gov) - Aug 24, 2016
P2, N=0, Withdrawn, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2017 --> Mar 2019 N=37 --> 0 | Terminated --> Withdrawn
- | patritumab (U3-1287) / Amgen, Daiichi Sankyo
Trial completion, Combination therapy, Metastases: Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer (clinicaltrials.gov) - Aug 24, 2016
P1b, N=15, Completed, Sponsor: Daiichi Sankyo Inc.
N=37 --> 0 | Terminated --> Withdrawn Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Orpathys (savolitinib) / AstraZeneca, Hutchmed
Trial initiation date: Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer (clinicaltrials.gov) - Aug 24, 2016
P1, N=33, Not yet recruiting, Sponsor: Yale University
Active, not recruiting --> Completed Initiation date: Jan 2016 --> Jan 2017
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: CheckMate 651: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Aug 24, 2016
P3, N=490, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 2016 --> Jan 2017 Trial primary completion date: Jan 2020 --> Jul 2018
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Enrollment change, Combination therapy, Metastases: REGAIN: Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study (clinicaltrials.gov) - Aug 23, 2016
P2, N=2, Active, not recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Trial primary completion date: Jan 2020 --> Jul 2018 Recruiting --> Active, not recruiting | N=60 --> 2
- ||| monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Aug 19, 2016
P1, N=232, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | N=60 --> 2 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Sep 2019
- Xalkori (crizotinib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Enrollment open, Metastases: Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma (clinicaltrials.gov) - Aug 17, 2016
P2, N=152, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Sep 2019 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial primary completion date, Combination therapy, Metastases: Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History (clinicaltrials.gov) - Aug 17, 2016
P1, N=24, Recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2016 --> Jul 2017
- Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, PD(L)-1 Biomarker, Surgery, Metastases: Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 17, 2016
P1/2, N=42, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Jul 2016 --> Jul 2017 Not yet recruiting --> Recruiting
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, WNT974 / Novartis, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment closed, Combination therapy, Metastases: Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations (clinicaltrials.gov) - Aug 16, 2016
P1/2, N=60, Active, not recruiting, Sponsor: Array BioPharma
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- pegvorhyaluronidase alfa (PEGPH20) / Halozyme, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection (clinicaltrials.gov) - Aug 15, 2016
P=N/A, N=10, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Sep 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment closed, Trial primary completion date, Metastases: POSIBA: Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab (clinicaltrials.gov) - Aug 11, 2016
P2, N=170, Active, not recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Dec 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment open: ACE-Lung: Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer (clinicaltrials.gov) - Aug 10, 2016
P2, N=170, Recruiting, Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Dec 2016 Not yet recruiting --> Recruiting